Edwards Lifesciences Corporation (EW)
| Market Cap | 46.25B |
| Revenue (ttm) | 5.82B |
| Net Income (ttm) | 1.43B |
| Shares Out | 606.50M |
| EPS (ttm) | 2.34 |
| PE Ratio | 32.59 |
| Forward PE | 27.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,904,760 |
| Open | 76.65 |
| Previous Close | 76.71 |
| Day's Range | 76.14 - 76.79 |
| 52-Week Range | 60.57 - 94.87 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 84.94 (+11.4%) |
| Earnings Date | Jan 30, 2024 |
About EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition,... [Read more]
Financial Performance
In 2022, EW's revenue was $5.38 billion, an increase of 2.86% compared to the previous year's $5.23 billion. Earnings were $1.52 billion, an increase of 1.25%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is $84.94, which is an increase of 11.40% from the latest price.
News
Edwards Lifesciences To Spin-Off Critical Care Unit In 2024
On December 7, 2024, Edwards Lifesciences EW Corporation (NYSE: EW, $76.90, Market Capitalization: $46.6 billion) in its annual investor call announced its plans to spin-off its Critical Care unit int...
Edwards Lifesciences to spin off critical care unit to focus on heart devices
Edwards Lifesciences said on Thursday it would spin off its critical care unit at the end of 2024 to concentrate on its larger heart devices business.
Edwards Lifesciences to spin off Critical Care unit, sets $1B stock buyback
Edwards Lifesciences Corp.'s stock EW, +0.93% rose 1.9% in premarket trading Thursday after it said it plans to form an independent company out of its Critical Care unit in a tax-free spinoff transact...
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's sharpened focus and strategy for longer-term growth, provide an update on its technology pipelin...
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION
SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two co...
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION
SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluat...
Edwards Lifesciences quarterly sales jump on robust demand for heart devices
Edwards Lifesciences Corp on Wednesday reported a 12% rise in third-quarter sales, helped by strong demand for the company's artificial heart valves and other devices.
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
IRVINE, Calif. , Oct. 25, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept.
FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE
SAN FRANCISCO , Oct. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stro...
EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK
IRVINE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcathete...
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023
IRVINE, Calif. , Oct. 18, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2023 after the market closes on Wednesday, Oc...
Exclusive: Edwards Lifesciences targeted in EU antitrust raid last week - sources
Edwards Lifesciences was raided by EU antitrust regulators at one of its facilities in an EU country a week ago, two people with direct knowledge of the matter told Reuters on Tuesday.
BetterInvesting™ Magazine Update on Edwards Lifesciences Corp. and 3M Company
TROY, Mich. , Aug. 29, 2023 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Edwards Lifesciences Corp. (NYSE:EW) as its "Stock to Stu...
Will Edwards Lifesciences Stock Recover To Its Pre-Inflation Shock Highs Of $130?
Investors still have concerns about a potential recession despite a steady decline in the inflation rate in response to the Fed's aggressive rate hike plan.
EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE
IRVINE, Calif., Aug. 28, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, Septembe...
You can still run with the stock market's bulls, but watch the exits
The stock market, as measured by the S&P 500 Index SPX, -0.64%), has been moving upward. The U.S. benchmark index is essentially crawling up the higher “modified Bollinger Bands” (mBB), which is a bi...
Edwards Lifesciences shares fall as slow heart-valve growth dulls forecast raise
Edwards Lifesciences Corp on Wednesday slightly raised its annual forecasts for sales and profit, but slower-than-expected revenue growth in the company's artificial heart valves dragged its shares do...
EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS
IRVINE, Calif. , July 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2023.
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 26, 2023
IRVINE, Calif. , July 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2023 after the market closes on Wednesday, July 26...
Edwards Lifesciences: Improving Patient Safety and Outcomes: EU-HYPROTECT Registry Demonstrates Reduced Time in Hypotension During Surgery Using Acumen HPI Software
NYON, Switzerland--(BUSINESS WIRE)--Edwards Lifesciences today announced the results of the EU-HYPROTECT registry which indicates that using Acumen HPI software may help reduce the duration and severi...
Edwards Lifesciences: Quality at a Bear Market Price
Edwards Lifesciences Corp. ( EW , Financial) is another of the stocks that suffered due to the 2022 bear market.
DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETY
PARIS , May 17, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) announced today that new data from the Benchmark Registry in Europe demonstrated the safety and effectiveness of this streamlined t...
EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA
LOS ANGELES , May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bi...